+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Idiopathic Pulmonary Fibrosis Forecast and Market Analysis for 2035

  • ID: 3797403
  • Drug Pipelines
  • 171 pages
  • Datamonitor Healthcare
1 of 2
Disease Overview
Idiopathic pulmonary fibrosis (IPF) is a type of interstitial lung disease in which scarring and thickening of the lung tissue occurs due to unknown causes. In turn, this fibrosis reduces the ability of alveoli to transport oxygen from the lungs to the bloodstream, and results in symptoms such as dyspnea, chronic dry cough, fatigue, and weight loss. While lung function and capacity steadily decline in most IPF patients, some experience a sudden, rapid increase in irreversible disease progression called acute exacerbation. The prognosis of patients with IPF remains poor as those who are ineligible for lung transplantation have few effective treatment options.

Market Snapshot
  • Ofev will succeed Esbriet as market leader following the release of favorable real-world evidence.
  • Treatment of IPF is evolving as mounting evidence and revised international guidelines support clinical decision-making.
  • IPF is a complex and fatal disease with most cases in older populations aged =50 years.
  • Ofev is overtaking Esbriet, as new real-world evidence suggest that its clinical profile in pivotal trials was understated.
  • Pipeline therapies producing proven risk reductions in all-cause mortality will command a price premium.
Note: Product cover images may vary from those shown
2 of 2
FORECAST: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)
Overview
Executive Summary
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Esbriet
Product Profile: Ofev

TREATMENT: IDIOPATHIC PULMONARY FIBROSIS (Published on 06 November 2017)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends

EPIDEMIOLOGY: IDIOPATHIC PULMONARY FIBROSIS (Published on 07 August 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

MARKETED DRUGS: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)
Overview
Executive Summary
Product Overview
Product Profile: Esbriet
Product Profile: Ofev

PIPELINE: IDIOPATHIC PULMONARY FIBROSIS (Published on 17 November 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Glpg1690
Product Profile (Late Stage): Pbi-4050
Product Profile (Late Stage): Prm-151
Product Profile (Late Stage): Pamrevlumab

LIST OF FIGURES
Figure 1: Idiopathic pulmonary fibrosis – current and future market dynamics analysis
Figure 2: The authors assessment summary of key marketed and pipeline drugs for idiopathic pulmonary fibrosis
Figure 3: Idiopathic pulmonary fibrosis drug sales across the US, Japan, and five major EU markets, by country, 2016–25
Figure 4: Idiopathic pulmonary fibrosis drug sales in the US, 2016–25
Figure 5: Total sales categorized by severity across the US, Japan, and five major EU markets, 2016–25
Figure 6: Patient-based forecast methodology for idiopathic pulmonary fibrosis
Figure 7: Price sources and calculations, by country
Figure 8: Esbriet for idiopathic pulmonary fibrosis – SWOT analysis
Figure 9: The authors drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
Figure 10: The authors drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
Figure 11: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 12: Ofev for idiopathic pulmonary fibrosis – SWOT analysis
Figure 13: The authors drug assessment summary of Ofev for idiopathic pulmonary fibrosis
Figure 14: The authors drug assessment summary of Ofev for idiopathic pulmonary fibrosis
Figure 15: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 16: Distribution of diagnosed idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by severity and country (%)
Figure 17: Estimated percentage of idiopathic pulmonary fibrosis patients in each severity who remain undiagnosed across the US, Japan, and five major EU markets
Figure 18: Estimated percentage of IPF patients who experience acute exacerbation in the US, Japan, and five major EU markets, by severity and country
Figure 19: Overview of the ATS/ERS/JRS/ALAT evidence-based guidelines for the treatment of idiopathic pulmonary fibrosis
Figure 20: Percentage of IPF patients who fall into each treatment category in the US, Japan, and five major EU markets, by severity and country
Figure 21: Top five pharmacological treatment regimens used in mild IPF patients across the US, Japan, and five major EU markets, by country
Figure 22: Top five pharmacological treatment regimens used in moderate IPF patients across the US, Japan, and five major EU markets, by country
Figure 23: Top five pharmacological treatment regimens used in severe IPF patients across the US, Japan, and five major EU markets, by country
Figure 24: Use of Esbriet and Ofev, whether alone or in a combination, across the US, Japan, and five major EU markets, by severity and country
Figure 25: Percentage use of Esbriet and Ofev as monotherapy and in each combination across the US, Japan, and five major EU markets, by severity
Figure 26: Patients who receive supplemental anti-gastroesophageal reflux medications across the US, Japan, and five major EU markets, by severity and country (%)
Figure 27: Non-pharmacological treatments used in mild idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Figure 28: Non-pharmacological treatments used in moderate idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Figure 29: Non-pharmacological treatments used in severe idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Figure 30: Trends in diagnosed incident cases of IPF in the US, Japan, and five major EU markets, by country, 2017–37
Figure 31: Trends in diagnosed prevalent cases of IPF in the US, Japan, and five major EU markets, by country, 2017–37
Figure 32: Esbriet for idiopathic pulmonary fibrosis – SWOT analysis
Figure 33: The authors drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
Figure 34: The authors drug assessment summary of Esbriet for idiopathic pulmonary fibrosis
Figure 35: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 36: Ofev for idiopathic pulmonary fibrosis – SWOT analysis
Figure 37: The authors drug assessment summary of Ofev for idiopathic pulmonary fibrosis
Figure 38: The authors drug assessment summary of Ofev for idiopathic pulmonary fibrosis
Figure 39: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country, 2016–25
Figure 40: GLPG1690 for idiopathic pulmonary fibrosis – SWOT analysis
Figure 41: The authors drug assessment summary of GLPG1690 for idiopathic pulmonary fibrosis
Figure 42: The authors drug assessment summary of GLPG1690 for idiopathic pulmonary fibrosis
Figure 43: PBI-4050 for idiopathic pulmonary fibrosis – SWOT analysis
Figure 44: The authors drug assessment summary of PBI-4050 for idiopathic pulmonary fibrosis
Figure 45: The authors drug assessment summary of PBI-4050 for idiopathic pulmonary fibrosis
Figure 46: PRM-151 for idiopathic pulmonary fibrosis – SWOT analysis
Figure 47: The authors drug assessment summary of PRM-151 for idiopathic pulmonary fibrosis
Figure 48: The authors drug assessment summary of PRM-151 for idiopathic pulmonary fibrosis
Figure 49: Pamrevlumab for idiopathic pulmonary fibrosis – SWOT analysis
Figure 50: The authors drug assessment summary of pamrevlumab for idiopathic pulmonary fibrosis
Figure 51: The authors drug assessment summary of pamrevlumab for idiopathic pulmonary fibrosis

LIST OF TABLES
Table 1: Summary of drug classes and molecules included in The authors idiopathic pulmonary fibrosis patientbased forecast
Table 2: Exchange rates used for calculating prices
Table 3: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
Table 4: Esbriet drug profile
Table 5: Esbriet Phase III data in idiopathic pulmonary fibrosis
Table 6: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 7: Ofev drug profile
Table 8: Ofev pivotal trial data in idiopathic pulmonary fibrosis
Table 9: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 10: Pulmonologists surveyed for the idiopathic pulmonary fibrosis primary research study, 2015
Table 11: Subtypes of idiopathic interstitial pneumonias
Table 12: The authors definition of idiopathic pulmonary fibrosis severity
Table 13: Estimated percentage of idiopathic pulmonary fibrosis patients in each severity who remain undiagnosed across the US, Japan, and five major EU markets
Table 14: Approved treatments available for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
Table 15: Off-label therapies used in the treatment of idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
Table 16: Non-pharmacological therapies used in the treatment of idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets
Table 17: Pharmacological treatment regimens used in mild idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Table 18: Pharmacological treatment regimens used in moderate idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Table 19: Pharmacological treatment regimens used in severe idiopathic pulmonary fibrosis patients across the US, Japan, and five major EU markets, by country
Table 20: Sources used for the epidemiological analysis of IPF in the US, Japan, and five major EU markets, by country
Table 21: Diagnosed incident cases of IPF in the US, Japan, and five major EU markets, by country, 2017–37
Table 22: Diagnosed prevalent cases of IPF in the US, Japan, and five major EU markets, by country, 2017–37
Table 23: Profiled key marketed drugs for idiopathic pulmonary fibrosis
Table 24: Esbriet drug profile
Table 25: Esbriet Phase III data in idiopathic pulmonary fibrosis
Table 26: Esbriet sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 27: Ofev drug profile
Table 28: Ofev pivotal trial data in idiopathic pulmonary fibrosis
Table 29: Ofev sales for idiopathic pulmonary fibrosis across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 30: Phase II pipeline products in development for idiopathic pulmonary fibrosis
Table 31: GLPG1690 drug profile
Table 32: GLPG1690 Phase II data in idiopathic pulmonary fibrosis
Table 33: PBI-4050 drug profile
Table 34: PBI-4050 Phase II data in idiopathic pulmonary fibrosis
Table 35: PRM-151 drug profile
Table 36: PRM-151 Phase II trial in idiopathic pulmonary fibrosis
Table 37: PRM-151 Phase I data in idiopathic pulmonary fibrosis
Table 38: Pamrevlumab drug profile
Table 39: Pamrevlumab Phase II data in idiopathic pulmonary fibrosis
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll